Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis

Summary

Double blind, randomized, placebo-controlled, multicenter pilot study on efficacy and safety of CBLB612 following single administration for neutropenia prophylaxis in breast cancer patients receiving doxorubicin and cyclophosphamide myelosuppressive chemotherapy

Timeline

Start

2015-12

Primary completion

2016-07

Completion

2016-07

Drugs

Indications